Monthly information on share capital and company voting rights
Cellectis announced its commitment to advancing CAR-T immunotherapies, focusing on off-the-shelf gene-edited T-cells for cancer treatment.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cellectis announced its commitment to advancing CAR-T immunotherapies, focusing on off-the-shelf gene-edited T-cells for cancer treatment. As of August 31, 2020, the company has 42,486,133 shares outstanding and 47,940,778 voting rights. Their innovative approach leverages TALEN® technology to target a range of cancers including AML, B-ALL, and MM. Headquartered in Paris, Cellectis is publicly traded on both Nasdaq (CLLS) and Euronext Growth (ALCLS). The company aims to meet urgent medical needs in oncology, leveraging over 20 years of gene editing expertise.
Positive
- Development of off-the-shelf CAR-T immunotherapies may result in significant market differentiation.
- Utilization of TALEN® gene-editing technology showcases innovation in cancer treatment.
- Focus on multiple high-need cancers (AML, B-ALL, MM) indicates broad market potential.
Negative
- None.
Details
News Market Reaction – CLLS
The recorded move for CLLS in the trading session of this news was -2.09%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
(Article 223-16 of General Regulation of the French financial markets authority)
NEW YORK, Sept. 07, 2020 (GLOBE NEWSWIRE) --
Listing market: Euronext Growth
ISIN code: FR0010425595
| Date | Total number of shares in the capital | Total number of voting rights |
| 08/31/2020 | 42,486,133 | 47,940,778 |
About Cellectis
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.
As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM).
Cellectis headquarters are in Paris, France, with additional locations in New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). For more information, visit www.cellectis.com.
Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.
TALEN® is a registered trademark owned by Cellectis.
For further information, please contact:
Media contacts:
Jennifer Moore, VP, Communications, 917-580-1088, media@cellectis.com
Caitlin Kasunich, KCSA Strategic Communications, 212-896-1241, ckasunich@kcsa.com
IR contact:
Simon Harnest, VP, Corporate Strategy and Finance, 646-385-9008, simon.harnest@cellectis.com
PDF available at: http://ml.globenewswire.com/Resource/Download/cb80f5e7-e4fa-458c-862b-575f7ec63538
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.